CTLA-4 inhibitors go to the source and increase the anti-cancer T-cell numbers, while PD-1 inhibitors act in peripheral blood or tumors, allowing the binding process of PD-1 to PD-L1 to be blocked in these viable agents, thus freeing ICs to kill and launch a strike against the tumor [127]. Here, CD274 is linked to neoplasm.